Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 7.32
KYTH's Cash to Debt is ranked higher than
76% of the 1173 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.65 vs. KYTH: 7.32 )
KYTH' s 10-Year Cash to Debt Range
Min: 3.54   Max: No Debt
Current: 7.32

F-Score: 3
Z-Score: 13.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -90.35
KYTH's ROE (%) is ranked lower than
54% of the 1157 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.46 vs. KYTH: -90.35 )
KYTH' s 10-Year ROE (%) Range
Min: -129.61   Max: -47.46
Current: -90.35

-129.61
-47.46
ROA (%) -64.63
KYTH's ROA (%) is ranked lower than
55% of the 1183 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.53 vs. KYTH: -64.63 )
KYTH' s 10-Year ROA (%) Range
Min: -97.98   Max: -38.51
Current: -64.63

-97.98
-38.51
ROC (Joel Greenblatt) (%) -6858.22
KYTH's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 1178 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.83 vs. KYTH: -6858.22 )
KYTH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -27136.04   Max: -3013.33
Current: -6858.22

-27136.04
-3013.33
» KYTH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

KYTH Guru Trades in Q2 2014

Steven Cohen 15,200 sh (unchged)
Jim Simons Sold Out
RS Investment Management 283,181 sh (-1.91%)
» More
Q3 2014

KYTH Guru Trades in Q3 2014

RS Investment Management 289,881 sh (+2.37%)
Steven Cohen Sold Out
» More
Q4 2014

KYTH Guru Trades in Q4 2014

RS Investment Management 359,371 sh (+23.97%)
» More
Q1 2015

KYTH Guru Trades in Q1 2015

George Soros 54,194 sh (New)
RS Investment Management 429,011 sh (+19.38%)
» More
» Details

Insider Trades

Latest Guru Trades with KYTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.60
KYTH's P/B is ranked higher than
51% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.13 vs. KYTH: 7.60 )
KYTH' s 10-Year P/B Range
Min: 6.69   Max: 17.83
Current: 7.6

6.69
17.83
EV-to-EBIT -10.39
KYTH's EV-to-EBIT is ranked higher than
59% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.19 vs. KYTH: -10.39 )
KYTH' s 10-Year EV-to-EBIT Range
Min: -21.8   Max: -7.3
Current: -10.39

-21.8
-7.3
Current Ratio 10.90
KYTH's Current Ratio is ranked higher than
95% of the 1051 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.20 vs. KYTH: 10.90 )
KYTH' s 10-Year Current Ratio Range
Min: 1.81   Max: 11.36
Current: 10.9

1.81
11.36
Quick Ratio 10.90
KYTH's Quick Ratio is ranked higher than
96% of the 1051 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. KYTH: 10.90 )
KYTH' s 10-Year Quick Ratio Range
Min: 1.81   Max: 11.36
Current: 10.9

1.81
11.36

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.60
KYTH's Price/Net Cash is ranked higher than
92% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. KYTH: 7.60 )
KYTH' s 10-Year Price/Net Cash Range
Min: 5.66   Max: 32.33
Current: 7.6

5.66
32.33
Price/Net Current Asset Value 7.60
KYTH's Price/Net Current Asset Value is ranked higher than
89% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. KYTH: 7.60 )
KYTH' s 10-Year Price/Net Current Asset Value Range
Min: 5.43   Max: 23.26
Current: 7.6

5.43
23.26
Price/Tangible Book 7.50
KYTH's Price/Tangible Book is ranked higher than
58% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. KYTH: 7.50 )
KYTH' s 10-Year Price/Tangible Book Range
Min: 5.42   Max: 23.14
Current: 7.5

5.42
23.14
Earnings Yield (Greenblatt) -8.90
KYTH's Earnings Yield (Greenblatt) is ranked lower than
55% of the 1170 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. KYTH: -8.90 )
KYTH' s 10-Year Earnings Yield (Greenblatt) Range
Min: -17.4   Max: 0
Current: -8.9

-17.4
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:KYT.Germany,
KYTHERA Biopharmaceuticals Inc was incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005, and it changed its name to AESTHERx, Inc. In July 2006, it changed its name to KYTHERA Biopharmaceuticals, Inc. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription aesthetic products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company's initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The Company's product candidate, ATX-101, is a potential first-in-class, injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and long-lasting results in the reduction of submental fat.
» More Articles for KYTH

Headlines

Articles On GuruFocus.com
My Portfolio Mar 08 2015 

More From Other Websites
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program May 19 2015
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program May 19 2015
KYTHERA BIOPHARMACEUTICALS INC Financials May 15 2015
Analyst Issues 5 Potential Biotech Buyout Candidates May 14 2015
KYTHERA Biopharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care... May 08 2015
KYTHERA Biopharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care... May 08 2015
Kythera reports 1Q loss May 07 2015
Kythera reports 1Q loss May 07 2015
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 07 2015
KYTHERA Biopharmaceuticals Releases First Quarter 2015 Operating Results and Progress Update May 07 2015
Q1 2015 KYTHERA Biopharmaceuticals Inc Earnings Release - After Market Close May 07 2015
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program May 06 2015
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program May 06 2015
Kythera's (KYTH) Double Chin Drug Kybella Gets FDA Nod - Analyst Blog May 04 2015
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 04 2015
KYTHERA Biopharmaceuticals to Release First Quarter 2015 Operating Results Apr 30 2015
KYTHERA Biopharmaceuticals to Release First Quarter 2015 Operating Results Apr 30 2015
Multimedia Release -- KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA(TM) (also known... Apr 30 2015
Multimedia Release -- KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA(TM) (also known... Apr 30 2015
FDA approves Westlake Village company's drug to reduce double-chin fat Apr 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK